Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.
D. Cota, S. Genghini, R. Pasquali, U. Pagotto
J Endocrinol Invest. 2003-10-01; 26(10): 1041-1044
DOI: 10.1007/bf03348205
Read on PubMed
J Endocrinol Invest. 2003-10-01; 26(10): 1041-1044
DOI: 10.1007/bf03348205
Read on PubMed
1. J Endocrinol Invest. 2003 Oct;26(10):1041-4.
Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.
Cota D(1), Genghini S, Pasquali R, Pagotto U.
Author information:
(1)Neuroendocrinology Group, Max-Planck-Institute of Psychiatry, Munich, Germany.
DOI: 10.1007/BF03348205
PMID: 14759080 [Indexed for MEDLINE]